Logo image of NPCE

NEUROPACE INC (NPCE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NPCE - US6412881053 - Common Stock

16.73 USD
-0.23 (-1.36%)
Last: 1/9/2026, 8:11:10 PM
16.9245 USD
+0.19 (+1.16%)
After Hours: 1/9/2026, 8:11:10 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NPCE. NPCE was compared to 185 industry peers in the Health Care Equipment & Supplies industry. NPCE has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, NPCE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year NPCE has reported negative net income.
In the past year NPCE has reported a negative cash flow from operations.
In the past 5 years NPCE always reported negative net income.
NPCE had a negative operating cash flow in each of the past 5 years.
NPCE Yearly Net Income VS EBIT VS OCF VS FCFNPCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

NPCE has a Return On Assets (-22.36%) which is in line with its industry peers.
The Return On Equity of NPCE (-129.53%) is worse than 65.95% of its industry peers.
Industry RankSector Rank
ROA -22.36%
ROE -129.53%
ROIC N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NPCE Yearly ROA, ROE, ROICNPCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

NPCE has a Gross Margin of 76.77%. This is amongst the best in the industry. NPCE outperforms 87.57% of its industry peers.
NPCE's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for NPCE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
NPCE Yearly Profit, Operating, Gross MarginsNPCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

3

2. Health

2.1 Basic Checks

NPCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NPCE has more shares outstanding
NPCE has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NPCE is higher compared to a year ago.
NPCE Yearly Shares OutstandingNPCE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
NPCE Yearly Total Debt VS Total AssetsNPCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

NPCE has an Altman-Z score of -2.21. This is a bad value and indicates that NPCE is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.21, NPCE is not doing good in the industry: 62.16% of the companies in the same industry are doing better.
NPCE has a Debt/Equity ratio of 3.17. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 3.17, NPCE is not doing good in the industry: 84.32% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.17
Debt/FCF N/A
Altman-Z -2.21
ROIC/WACCN/A
WACC10.11%
NPCE Yearly LT Debt VS Equity VS FCFNPCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

NPCE has a Current Ratio of 4.86. This indicates that NPCE is financially healthy and has no problem in meeting its short term obligations.
NPCE has a better Current ratio (4.86) than 77.30% of its industry peers.
A Quick Ratio of 3.94 indicates that NPCE has no problem at all paying its short term obligations.
The Quick ratio of NPCE (3.94) is better than 74.59% of its industry peers.
Industry RankSector Rank
Current Ratio 4.86
Quick Ratio 3.94
NPCE Yearly Current Assets VS Current LiabilitesNPCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.00% over the past year.
Looking at the last year, NPCE shows a very strong growth in Revenue. The Revenue has grown by 24.08%.
The Revenue has been growing by 16.67% on average over the past years. This is quite good.
EPS 1Y (TTM)24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.11%
Revenue 1Y (TTM)24.08%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%29.89%

3.2 Future

NPCE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.32% yearly.
NPCE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.59% yearly.
EPS Next Y18.4%
EPS Next 2Y14.93%
EPS Next 3Y19.38%
EPS Next 5Y19.32%
Revenue Next Year22.86%
Revenue Next 2Y11.27%
Revenue Next 3Y16.07%
Revenue Next 5Y18.59%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NPCE Yearly Revenue VS EstimatesNPCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
NPCE Yearly EPS VS EstimatesNPCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NPCE. In the last year negative earnings were reported.
Also next year NPCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NPCE Price Earnings VS Forward Price EarningsNPCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NPCE Per share dataNPCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as NPCE's earnings are expected to grow with 19.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.93%
EPS Next 3Y19.38%

0

5. Dividend

5.1 Amount

NPCE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

NEUROPACE INC

NASDAQ:NPCE (1/9/2026, 8:11:10 PM)

After market: 16.9245 +0.19 (+1.16%)

16.73

-0.23 (-1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners71.36%
Inst Owner Change0%
Ins Owners2.5%
Ins Owner Change-0.03%
Market Cap553.43M
Revenue(TTM)94.86M
Net Income(TTM)-23.99M
Analysts84.29
Price Target19 (13.57%)
Short Float %3.73%
Short Ratio4.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.24%
Min EPS beat(2)-14.56%
Max EPS beat(2)45.05%
EPS beat(4)3
Avg EPS beat(4)16.51%
Min EPS beat(4)-14.56%
Max EPS beat(4)45.05%
EPS beat(8)7
Avg EPS beat(8)17.82%
EPS beat(12)11
Avg EPS beat(12)18.53%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)1
Avg Revenue beat(2)4.37%
Min Revenue beat(2)-0.11%
Max Revenue beat(2)8.86%
Revenue beat(4)2
Avg Revenue beat(4)2.31%
Min Revenue beat(4)-0.6%
Max Revenue beat(4)8.86%
Revenue beat(8)6
Avg Revenue beat(8)3.06%
Revenue beat(12)10
Avg Revenue beat(12)6.97%
Revenue beat(16)13
Avg Revenue beat(16)5.57%
PT rev (1m)6.43%
PT rev (3m)10.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.65%
EPS NY rev (1m)0%
EPS NY rev (3m)10.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.83
P/FCF N/A
P/OCF N/A
P/B 29.89
P/tB 29.89
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS2.87
BVpS0.56
TBVpS0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.36%
ROE -129.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.77%
FCFM N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
F-Score5
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 3.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.99%
Cap/Sales 0.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.86
Quick Ratio 3.94
Altman-Z -2.21
F-Score5
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)156.88%
Cap/Depr(5y)123.33%
Cap/Sales(3y)0.66%
Cap/Sales(5y)0.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.11%
EPS Next Y18.4%
EPS Next 2Y14.93%
EPS Next 3Y19.38%
EPS Next 5Y19.32%
Revenue 1Y (TTM)24.08%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%29.89%
Revenue Next Year22.86%
Revenue Next 2Y11.27%
Revenue Next 3Y16.07%
Revenue Next 5Y18.59%
EBIT growth 1Y21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.63%
EBIT Next 3Y35.11%
EBIT Next 5YN/A
FCF growth 1Y32.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.61%
OCF growth 3YN/A
OCF growth 5YN/A

NEUROPACE INC / NPCE FAQ

Can you provide the ChartMill fundamental rating for NEUROPACE INC?

ChartMill assigns a fundamental rating of 2 / 10 to NPCE.


What is the valuation status of NEUROPACE INC (NPCE) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUROPACE INC (NPCE). This can be considered as Overvalued.


How profitable is NEUROPACE INC (NPCE) stock?

NEUROPACE INC (NPCE) has a profitability rating of 1 / 10.


What is the expected EPS growth for NEUROPACE INC (NPCE) stock?

The Earnings per Share (EPS) of NEUROPACE INC (NPCE) is expected to grow by 18.4% in the next year.